EP0646010A4 - Hormone antimullerienne utilisee pour le traitement de tumeurs et la modulation de l'expression de l'antigene d'histocompatibilite majeure classe i. - Google Patents

Hormone antimullerienne utilisee pour le traitement de tumeurs et la modulation de l'expression de l'antigene d'histocompatibilite majeure classe i.

Info

Publication number
EP0646010A4
EP0646010A4 EP93916585A EP93916585A EP0646010A4 EP 0646010 A4 EP0646010 A4 EP 0646010A4 EP 93916585 A EP93916585 A EP 93916585A EP 93916585 A EP93916585 A EP 93916585A EP 0646010 A4 EP0646010 A4 EP 0646010A4
Authority
EP
European Patent Office
Prior art keywords
müllschcher
antiques
modulating
class
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93916585A
Other languages
German (de)
English (en)
Other versions
EP0646010A1 (fr
Inventor
Patricia K Donahoe
Tai Wai Chin
Robert L Parry
James Epstein
Richard C Ragin
David T Maclaughlin
Edward M Barksdale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP0646010A1 publication Critical patent/EP0646010A1/fr
Publication of EP0646010A4 publication Critical patent/EP0646010A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP93916585A 1992-06-19 1993-06-18 Hormone antimullerienne utilisee pour le traitement de tumeurs et la modulation de l'expression de l'antigene d'histocompatibilite majeure classe i. Withdrawn EP0646010A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90163792A 1992-06-19 1992-06-19
US901637 1992-06-19
US712593A 1993-01-21 1993-01-21
US7125 1993-01-21
PCT/US1993/005791 WO1994000133A1 (fr) 1992-06-19 1993-06-18 Hormone antimullerienne utilisee pour le traitement de tumeurs et la modulation de l'expression de l'antigene d'histocompatibilite majeure classe i.

Publications (2)

Publication Number Publication Date
EP0646010A1 EP0646010A1 (fr) 1995-04-05
EP0646010A4 true EP0646010A4 (fr) 1997-04-23

Family

ID=26676562

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93916585A Withdrawn EP0646010A4 (fr) 1992-06-19 1993-06-18 Hormone antimullerienne utilisee pour le traitement de tumeurs et la modulation de l'expression de l'antigene d'histocompatibilite majeure classe i.

Country Status (2)

Country Link
EP (1) EP0646010A4 (fr)
WO (1) WO1994000133A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558241A (en) * 1994-01-06 1996-09-24 Temp Top Container Systems, Inc. Cryotransport chamber
WO2001055212A2 (fr) * 2000-01-27 2001-08-02 The General Hospital Corporation Administration de produits biologiques therapeutiques a partir de matrices tissulaires implantables
WO2008116161A2 (fr) 2007-03-22 2008-09-25 The General Hospital Corporation Pyrazoloanthrone et dérivés de celle-ci pour le traitement du cancer et d'états avec excès d'androgène
US9289492B2 (en) 2007-07-17 2016-03-22 The General Hospital Corporation Collecting ovarian cancer stem cells from ovarian cancer cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011687A (en) * 1984-06-18 1991-04-30 The General Hospital Corporation Purified Mullerian inhibiting substance and process for treating human ovarian cancer cells
WO1992007943A1 (fr) * 1990-10-31 1992-05-14 Somatix Therapy Corporation Vecteurs de retrovirus efficaces en therapie genique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622891B2 (en) * 1985-10-30 1992-04-30 Biogen, Inc. Cleaved dimers of mullerian inhibiting substance-like polypeptides
EP0584287B1 (fr) * 1991-04-12 2000-08-30 The General Hospital Corporation Purification de l'hormone antimullerienne pour le traitement de certaines tumeurs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011687A (en) * 1984-06-18 1991-04-30 The General Hospital Corporation Purified Mullerian inhibiting substance and process for treating human ovarian cancer cells
WO1992007943A1 (fr) * 1990-10-31 1992-05-14 Somatix Therapy Corporation Vecteurs de retrovirus efficaces en therapie genique

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CATE R.L. ET AL.: "Isolation of the bovine and human genes for Müllerian Inhibiting Substance and expression of the human gene in animal cells.", CELL, vol. 45, June 1986 (1986-06-01), pages 685 - 698, XP002024939 *
KASID A. ET AL: PNAS, 1990, vol. 87, pages 473-477, 'Human gene transfer: Characteriztion of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man' *
MACLAUGHLIN D.T.: "Mullerian duct regression and antiproliferative bioactivities of Mullerian Inhibiting Substance reside in its carboxy-terminal domain.", ENDOCRINOLOGY, vol. 131, no. 1, July 1992 (1992-07-01), pages 291 - 296, XP000644378 *
PEPINSKY R.B. ET AL.: "Proteolytic processing of Mullerian Inhibiting Substance produces a transforming growth factor-beta-like fragment.", J.BIOL.CHEM., vol. 263, no. 35, 1988, pages 18961 - 18964, XP002024938 *
RAGIN R.C.: "Human Mullerian Inhibiting Substance: Enhanced purification imparts biochemical stability and restores antiproliferation effect.", PROTEIN EXPRESSION AND PURIFICATION, vol. 3, no. 3, 22 June 1992 (1992-06-22), pages 236 - 245, XP000644388 *
See also references of WO9400133A1 *
SEGEV D.L. ET AL: "Müllerian inhibiting substance inhibits breast cancer cell growth through an NFkB-mediated pathway", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 37, 15 September 2000 (2000-09-15), pages 28371 - 28379, XP002382653, DOI: doi:10.1074/jbc.M004554200 *
SEGEV D.L. ET AL: "Müllerian inhibiting substance regulates NFKB signaling and growth of mammary epithelial cells in vivo", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 29, 20 July 2001 (2001-07-20), pages 26799 - 26806 *
TEIXEIRA J. ET AL: "Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level", ENDOCRINOLOGY, vol. 140, no. 10, October 1999 (1999-10-01), pages 4732 - 4738 *

Also Published As

Publication number Publication date
WO1994000133A1 (fr) 1994-01-06
EP0646010A1 (fr) 1995-04-05

Similar Documents

Publication Publication Date Title
EP0735870A4 (fr) Utilisation d'inhibiteurs de pla 2? pour traiter la maladie d'alzheimer
DE69224080D1 (de) Verwendung von nsaid zur behandlung von demenz
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
EP0840608A4 (fr) Traitement et prevention de neoplasmes avec des sels d'aminoimidazole carboxamide et de 5-amino-/5-(amino substitue)-1,2,3-triazoles
ATA105892A (de) Nagellack zur behandlung von onychomykosis enthaltend terbinafine
DE59609235D1 (de) Verwendung von aerogelen in der landwirtschaft
EP0709090A3 (fr) Compositions pour le traitement de tumeurs résistantes
DE69227883D1 (de) Riechstoffmikrokapseln zur Behandlung von Wäsche
DE69331265D1 (de) Verbindungen zur behandlung von entzündlichen erkrankungen und zur hemmung der produktion von tumornekrosefaktor
EP0675723A4 (fr) Therapie utilisant des bisphosphonates et des strogenes en vue de traiter et de prevenir la resorption osseuse.
DE69827126D1 (de) Verwendung von hypothalamus-hemmfaktor zur behandlung von ischämischen herzstörungen
DE3751527D1 (de) Zusammensetzungen zur Modulation der Effekten von TNF und IL-1.
EP0758894A4 (fr) UTILISATION DE COMPOSES SPECIFIQUES DES RECEPTEURS -g(a) 1C?-ADRENERGIQUES POUR LE TRAITEMENT DE L'ADENOME PROSTATIQUE
ATE174895T1 (de) Aromatische inhibitoren von acetylcholinesterase
DE69314234D1 (de) Konservierte Polysiloxanemulsion zur Behandlung von Geweben
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
ATE6464T1 (de) Verwendung von kosmetischen mitteln zur behandlung der haare und der kopfhaut.
DE69331833D1 (de) Verwendung von vitamin d-glykosiden zur behandlung oder prävention von osteoporose
DE69301904D1 (de) Zusammensetzung zur behandlung von keratinfasern
DE69015297D1 (de) Thermische Behandlung von schweren Erdölen.
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
DE69325141D1 (de) Behandlung von lignozellulosehaltigen Materialien
EP0646010A4 (fr) Hormone antimullerienne utilisee pour le traitement de tumeurs et la modulation de l'expression de l'antigene d'histocompatibilite majeure classe i.
DE59705697D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
DE69405736D1 (de) Anionische alkylgalaktosiduronate-tenside und kationische polymere enthaltende kosmetische zusammensetzungen und ihre verwendung zur behandlung von keratinösen substanzen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE DK ES FR GB IE IT LI NL PT SE

RHK1 Main classification (correction)

Ipc: C12N 15/16

A4 Supplementary search report drawn up and despatched

Effective date: 19970306

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): CH DE DK ES FR GB IE IT LI NL PT SE

17Q First examination report despatched

Effective date: 19991221

RTI1 Title (correction)

Free format text: USE OF MULLERIAN INHIBITING SUBSTANCE FOR TREATING TUMORS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101ALI20060215BHEP

Ipc: C12N 15/86 20060101ALI20060215BHEP

Ipc: C12N 5/10 20060101ALI20060215BHEP

Ipc: C12N 15/16 20060101AFI20060215BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE GENERAL HOSPITAL CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060704